Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Aurora Cannabis ( (TSE:ACB) ) just unveiled an announcement.
Aurora Cannabis reported the results of its 2026 Annual General Meeting of Shareholders, held virtually on August 7, 2026, with 16,639,306 common shares represented, equal to 26.86% of shares outstanding on the record date. Shareholders elected all board nominees with support levels above 85% of votes cast, confirming Miguel Martin and four other directors to the board.
Investors also approved the reappointment of Ernst & Young LLP as auditor for the coming year and passed the advisory “say-on-pay” resolution with 82.97% support, endorsing the company’s executive compensation approach. Management framed the strong voting outcomes as a signal of shareholder confidence in Aurora’s board and its medical-first strategy, underpinning efforts to grow the global medical cannabis business and create long-term value.
The most recent analyst rating on (TSE:ACB) stock is a Hold
with a C$4.00 price target.
To see the full list of analyst forecasts on Aurora Cannabis stock,
see the TSE:ACB Stock Forecast page.
Spark’s Take on ACB Stock
According to Spark, TipRanks’ AI Analyst, ACB is a Neutral.
Overall score is held back primarily by weak financial performance (losses and negative free cash flow despite a strong, low-debt balance sheet). Earnings call factors provide some support via reaffirmed outlook, expected sequential improvement, and strong international-margin profile, but technicals remain mixed with a longer-term downtrend, and valuation is constrained by negative earnings.
To see Spark’s full report on ACB stock,
click here.
More about Aurora Cannabis
Aurora Cannabis Inc., headquartered in Edmonton, Alberta, is a Canadian-based global leader in medical cannabis focused on improving patient lives through scientific expertise and high-quality products. The company serves medical markets across Canada, Europe, Australia and New Zealand under brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corporation, supported by GMP-certified facilities in Canada and Germany and listings on NASDAQ and TSX under the ticker ACB.
With a strategy centered on medical cannabis, Aurora aims to strengthen its global footprint and deliver consistent, high-quality products for patients. The company leverages world-class manufacturing standards and a team of industry professionals to expand its presence in regulated medical markets, positioning itself as a key player in international cannabis therapeutics and patient care.
YTD Price Performance: -28.08%
Average Trading Volume: 384,974
Technical Sentiment Signal: Sell
Current Market Cap: C$269.2M
Find detailed analytics on ACB stock on TipRanks’ Stock Analysis page.